A novel coronavirus emerged in China in late 2019; it has been officially named by the World Health Organization (WHO) as COVID-19. LabRoots will be working to educate the community about this pathogen in an ongoing series of virtual events.
Our 2020 Coronavirus Virtual Event Series including (4/2, 6,17, 9/17 and 12/3 events) were indeed a tremendous success! The event (s) are now available for on-demand viewing. Our next set of presentations will go live on April 14th, 2021.
June 17th Keynote Speaker: Stephen S. Morse, PhD, FAAM, F.A.C.E.
This virus is a member of the coronavirus family and is zoonotic, or transmissible from animals to humans, and is thought to have originated in bats like other coronaviruses. Researchers are working to learn more about how this virus made the jump from animals to humans, probably through an intermediate species.
The COVID-19 virus has already infected tens of thousands of people worldwide. In China, hundreds have been killed, leading the World Health Organization to declare an international health emergency, one of only four that have ever been declared.
Researchers have found evidence that the virus can be transmitted by people that don't have symptoms. Scientists are working to find ways to treat the fever, respiratory illness, cough, and breathing difficulties it causes.
You can learn more from this event about:
This free event does not require any travel, and will remain ongoing; webinars will continue to occur in the future as we find out more about this pathogen. The content will be available for unlimited, on-demand viewing. The global community will be able to interact using chat sessions and live-streaming. This seamless connectivity will be available on any desktop or mobile device so you can view, learn, and interact.
Call for Posters — Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary and discuss results with interested colleagues through email. Plan now to have your poster included in the Coronavirus Virtual Event Series and virtual event. Submission is free. Submit your abstract here.
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this virtual event series, you can earn 1 Continuing Education credit per presentation.
Use #LRcoronavirus to follow the conversation!
Brian Krueger, PhD, is an Associate Vice President and Technical Director in R&D at Labcorp. His areas of focus are high throughput exome and genome sequencing, Molecular Microbiology, and high throughput lab automation. He and the Molecular Microbiology R&D group at Labcorp developed and received FDA Emergency Use Authorization for the LabCorp COVID-19 RT-PCR Test. Recently, Labcorp was awarded a SARS-CoV-2 sequencing surveillance contract with the CDC as a direct result of the R&D team's work in sequencing and characterizing thousands of viral genomes from early on in the pandemic. Dr. Krueger received his PhD in Molecular and Cellular Biology from the University of Iowa in 2009. He then spent 3 years at the University of Florida employing genetic manipulation and high throughput sequencing techniques to create hundreds of viral mutants of Kaposi Sarcoma Herpesvirus and Murine Herpesvirus 68. In 2012, Dr. Krueger transitioned from viruses to humans and spent 3 years overseeing Dr. David Goldstein's high throughput human genetics sequencing lab at Duke University and transitioned that lab to Columbia University Medical Center in 2014. He joined Labcorp in 2015 where he has continued to focus on diagnostic assay development in both rare disease genetics and infectious disease.
Dr. Jordan RoseFigura completed her Ph.D. in Chemistry at UC Berkeley where she studied the mechanism of PQQ formation. After that, she was an NIH Postdoctoral Fellow at The Rockefeller University where she investigated small molecule inhibition of bacterial infection. At Swift, Jordan focuses on targeted sequencing and custom projects. She leads the custom amplicon laboratory and also works to develop new targeted technologies. Since starting at Swift, she has developed the Swift Normalase® Amplicon Panel (SNAP) workflow, 8 off-the-shelf amplicon panels, and the Swift indexes.
Pedro Echave has a Ph.D. in Biochemistry with more than 10 years of experience in genomic projects. He joined PerkinElmer 2 years ago as an NGS specialist for the EMEA region. As of May 2020, he has been serving as a Global Product Specialist for NGS.
Subodh Nimkar is a Senior Product Manager in MGI based in Complete Genomics facility in San Jose CA. His primary responsibilities include management and commercialization of the novel CoolMPS Chemistry for Massively Parallel Sequencing on DNBSEQ platforms. He is also responsible for product management and commercialization of MGIs sequencing solutions in AMERICAS. Over last 20 years he has worked with ABI, Thermo Fisher, Agilent and Streck. He has authored two key patents at ABI and commercialized solutions based on that. He holds a Masters in Chemical Engineering and MBA.
Anthony Tong is a Director of Product Management at BGI Americas. He has broad experience in the genomics and diagnostics space, covering oncology and infectious disease testing, companion diagnostics, biomarker and diagnostics development, and non-invasive prenatal testing. He currently leads product marketing for BGI’s COVID-19 solution and previously managed the company’s NGS solution for the biopharma industry in North America. Anthony received his PhD in Chemical Engineering from Columbia University and MBA from University of California, San Diego.
Manohar Furtado is a Director for R & D at Thermo Fisher Scientific. He has been working in the Life Sciences & Clinical Diagnostics for over 25 years. He has a PhD in Biology from the University of Poona and a Business Certification from the Sloan School of Management at MIT. Dr. Furtado worked as an Assistant Professor of Infectious Diseases & Pathology, the Director for Biotechnology, and the CLIA lab Director. He was with Applied Biosystems and Life Technologies in R & D for 13 years. He was on the National Biodefense Science Board at DHHS to implement bio surveillance policies. He has been involved in discovery research, clinical diagnostic testing, product development and commercialization, M & A activity with key acquisitions, fund raising and in defining strategy. He has been the recipient of several grants from funding agencies, has over 90 publications, and has presented at over 200 conferences on various topics related to human health and safety.
Russell Garlick, PhD, is the Chief Scientific Officer at LGC SeraCare Life Sciences. Since 2012 he has been focusing on expanding the company’s technologies, R&D organization, and product development pipeline. Throughout his career he has worked on the development, regulatory approval, and launch of a variety of technologies and assays, including an HIV/AIDS patient management program, molecular genomics technologies, and HIV drug discovery systems. Prior to joining LGC Clinical Diagnostics, Dr. Garlick was co-founder of Life Sciences Group and served as CEO and CTO of Protein Forest, Inc. He has also held executive R&D positions at PerkinElmer Life Sciences and DuPont NEN Life Sciences.
Nathan A. Ledeboer, PhD, is a Professor and Vice Chair of Pathology and Medical Director of Microbiology, Molecular Diagnostics, reference services, and Laboratory Client Services at Froedtert Hospital and Wisconsin Diagnostic Laboratories in Milwaukee, WI. His research endeavors, particularly in the area developing diagnostic tools for infectious diseases, have led to numerous publications in peer-reviewed journals and more than 100 funded research projects. Dr. Ledeboer is also a senior editor for the Journal of Clinical Microbiology.
Dr. Jackson has over 10 years of experience in genetic analysis technologies. As a senior member of the Content Engine R&D team at Thermo Fisher Scientific, he helps develop solutions for the research and healthcare markets, leveraging varied technologies such as capillary electrophoresis, digital PCR, next-generation sequencing, and microarray analysis. Before Thermo Fisher Scientific, he was at Nanostring Technologies running the Field Applications Specialist (FAS) team. He was also an Acting Assistant Professor at University of Washington, Department of Genome Sciences, investigating developmental genetics of Drosophila melanogaster.
Dr. Memoli is a graduate of the College of William and Mary and he received his master’s degree in microbiology from Thomas Jefferson University in Philadelphia, PA. He then received his medical degree from St George’s University School of Medicine. He completed a residency in internal medicine at the Washington Hospital Center Georgetown University Internal Medicine Program in Washington, DC. After completing an infectious disease fellowship in NIAID at the National Institutes of Health, Dr. Memoli developed a clinical/translational research program to study influenza and other respiratory viruses in the Laboratory of Infectious Diseases. He now serves as the Director of the LID Clinical Studies Unit (CSU) that seeks to perform translational research studies to answer fundamental questions regarding human influenza, respiratory viruses, and other emerging viral infections to inform and impact future vaccine and therapeutic design, while also making an effort to assist in evaluation of novel products that may impact human health. With a focus on healthy volunteer research, the LID CSU has been able to continue their primary work on influenza while quickly able to respond to assist in research of emerging infections. Dr. Memoli is considered a leading expert in healthy volunteer challenge trials, respiratory virus infections, and influenza vaccines. In addition, in recent years Dr. Memoli’s LID CSU has been heavily involved in the NIH response to emerging threats including the 2009 Influenza Pandemic, Zika, EBOLA, and COVID19.
Ali H. Mokdad, PhD, is Professor of Health Metrics Sciences at the Institute for Health Metrics and Evaluation (IHME) and Chief Strategy Officer for Population Health at the University of Washington. Prior to IHME, Dr. Mokdad worked at the US Centers for Disease Control and Prevention. He has published groundbreaking research on local-level disease trends and leading risk factors for poor health. His work on obesity is among the most highly cited in the field.
Dr. Shuting Xu received her PhD degree from Hanover medical school in Germany. Before, she holds a Master’s degree in Biology from University of Ulm, Germany and a Bachelor’s degree in Biology from Nanjing Agricultural University. Her research during PhD and Postdoc periods were mainly focused on virus-related innate immune response and HIV-1 restriction factors. Her publication "cGAS-Mediated Innate Immunity Spreads Intercellularly through HIV-1 Env-Induced Membrane Fusion Sites" on Cell Host & Microbe has received the German AIDS prize that year. Dr. Xu currently works at GenScript Europe as Field Application Scientist.
Harm van Bakel, PhD, is an Assistant Professor of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai (ISMMS) and co-director of the Mount Sinai Health System Pathogen Surveillance Program. His research interests are focused on applying novel genomics technologies to fundamental problems in infectious disease to understand pathogen-host interactions and the molecular basis of evolution and transmission of viruses and bacteria, to ultimately provide insights into new treatment options and approaches to prevent the spread of infectious diseases.
Dr. Schroth is currently a Vice President and Distinguished Scientist at Illumina where he leads the Emerging Applications Group in Product Development. He has been with Illumina for 16 years. Dr. Schroth works on developing NGS tools to study genomics, gene expression and regulation and applies these tools to projects in the fields of cancer, immunology, microbiology and infectious disease. Over the course of his career Dr. Schroth has been an author on more than 100 peer reviewed research papers and holds 17 U.S. patents.
After studying Natural Sciences at Cambridge University, Richard Michelmore joined the faculty of University of California at Davis in 1982. Richard was the founding Director of the Genome Center at UC Davis in 2003. He is currently a Distinguished Professor in the Departments of Plant Sciences, Molecular & Cellular Biology, and Medical Microbiology & Immunology. His multidisciplinary research utilizes molecular, genetic, and evolutionary approaches to plant genomics and he has published over 200 scientific papers. In particular, he aims to exploit such approaches for information-driven deployment of resistance genes in crop plants to provide more durable disease resistance. In addition, he is interested in fostering research to enhance global food security. His interests also include applications of DNA sequencing to all areas of biology and its increasing impact on society. In response to the current pandemic, he has been a major contributor to the team providing rapid, high throughput testing for SARS-CoV-2 to the UC Davis campus and the City of Davis and is now deploying rapid genotyping to monitor for variants of concern.
Corey Casper is the Chief Executive Officer at the Infectious Disease Research Institute (IDRI). At IDRI, Dr. Casper oversees a portfolio of vaccines, therapeutics, and diagnostics that provide comprehensive solutions to global health problems. These include immune-enhancing adjuvant formulations that enable strong, safe and durable vaccines, a novel RNA vaccine platform for the prevention of pandemic / emerging viruses, and products for the treatment and prevention of cancer in low- and middle-income countries.
Dr. Casper received his medical degree from Cornell University, and completed Residency in Internal Medicine at the University of California – San Francisco and Fellowship in Infectious Disease at the University of Washington, where he also earned a Masters of Public Health. His research focuses on the relationship between infectious diseases, immunity and cancer. He has authored more than 125 peer-reviewed publications, and has received funding as the Principal Investigator of more than 100 million dollars in NIH and industry-sponsored studies. Key contributions to science include the development and deployment of diagnostic assays for tumor viruses, design and execution of Phase 1 and Phase 2 vaccine trials, leadership of multi-phased international immunotherapy clinical trials from conception to publication culminating in FDA licensure, epidemiologic and cost effectiveness analyses, and translational studies of the virologic and immunologic basis of infectious diseases and cancer.
Dr. Casper is also a committed educator and clinician. He is a Clinical Professor of Medicine and Global Health at the University of Washington (where he is the Associate Director of the Center for AIDS Research) and an Affiliate Professor in the Vaccine and Infectious Disease Division at the Fred Hutchinson Cancer Research Center (where he served as Associate Cancer Center Director and Founding Head of the Global Oncology Program). Dr Casper cares for patients with infectious diseases and cancer at the Seattle Cancer Care Alliance and the University of Washington Medical Center.
Dr. Goepfert holds the Edward W. Hook III, MD Endowed Professorship in Infectious Diseases in the Department of Medicine at the University of Alabama at Birmingham (UAB) and the Director of the Alabama Vaccine Research Clinic (AVRC). His laboratory research interests are focused on T cell immunology and vaccine design. He has recently begun analyzing T cell responses to COVID-19 using samples obtained from patients at UAB. Dr. Goepfert’s clinical research interest is centered on the testing of preventative vaccines through the AVRC which has previously focused on HIV but now is studying COVID-19 vaccines as well. He has also overseen vaccines trials designed to prevent anthrax, HPV, HBV, influenza, and small pox. He is authored over 140 peer-reviewed papers largely focused on immunology and vaccines.
Mike has over 10 years’ experience in the molecular diagnostics industry with a track record of delivering high quality products. He oversees Product Development activities at Yourgene Health, ensuring compliance to quality and regulatory standards.
Prior to joining Yourgene Health, formerly Premaitha Health, he successfully led the product design and development of QIAGEN’s companion diagnostic systems from project inception through to FDA approval. This included the design and development of assay reagents, software and utilisation of automated instruments and additional regulatory registrations including CE marking, Canadian and Japanese approvals.
Mike played a key role in mapping the product development process for a diagnostic assay then utilising this to make improvements to processes and projects. Mike has a PhD from University of Manchester, where he also spent two years as a Post-Doctoral Research Associate, and a BSc (Hons) in Human Genetics from the University of Nottingham.